Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor
暂无分享,去创建一个
M. Meyerson | J. Francis | S. Beck | A. Feber | S. Asa | T. Meyer | O. Ogunbiyi | D. Oukrif | M. Novelli | C. Thirlwell | S. Serra | T. Luong | M. Caplin | M. Kulke | T. Morris | M. Pericleous | D. Mandair | C. Toumpanakis | A. Karpathakis | H. Dibra | M. Mohmaduvesh | Chistodoulos Pipinikas
[1] P. Hellman,et al. Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors , 2015, Annals of Surgical Oncology.
[2] Gangning Liang,et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. , 2014, Cancer cell.
[3] Johan Staaf,et al. Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome , 2014, Clinical Cancer Research.
[4] J. Reubi,et al. The Glucose-Dependent Insulinotropic Polypeptide Receptor: A Novel Target for Neuroendocrine Tumor Imaging—First Preclinical Studies , 2014, The Journal of Nuclear Medicine.
[5] C. Larsson,et al. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors , 2014, Epigenetics.
[6] Martin Vingron,et al. Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids , 2014, Nature Communications.
[7] R. Versteeg. Cancer: Tumours outside the mutation box , 2014, Nature.
[8] G. Åkerström,et al. Global DNA methylation patterns through an array-based approach in small intestinal neuroendocrine tumors. , 2014, Endocrine-related cancer.
[9] Andrew E. Teschendorff,et al. ChAMP: 450k Chip Analysis Methylation Pipeline , 2014, Bioinform..
[10] A. Teschendorff,et al. Using high-density DNA methylation arrays to profile copy number alterations , 2014, Genome Biology.
[11] Robert Lowe,et al. Marmal-aid – a database for Infinium HumanMethylation450 , 2013, BMC Bioinformatics.
[12] Trevor J Pugh,et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors , 2013, Nature Genetics.
[13] C. Larsson,et al. Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization , 2013, BMC Cancer.
[14] Jing Wang,et al. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 , 2013, Nucleic Acids Res..
[15] Sean R. Davis,et al. NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..
[16] S. Duffy,et al. Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. , 2012, Cancer biomarkers : section A of Disease markers.
[17] A. Hartmann,et al. Gastrointestinal , Hepatobiliary , and Pancreatic Pathology Methylation-Dependent Activation of CDX 1 through NF-B A Link from Inflammation to Intestinal Metaplasia in the Human Stomach , 2012 .
[18] Reiner Schulz,et al. Resources for methylome analysis suitable for gene knockout studies of potential epigenome modifiers , 2012, GigaScience.
[19] Ning Li,et al. Promoter Hypermethylation Mediated Downregulation of FBP1 in Human Hepatocellular Carcinoma and Colon Cancer , 2011, PloS one.
[20] Hiroyuki Yamamoto,et al. Co-expression of laminin β3 and γ2 chains and epigenetic inactivation of laminin α3 chain in gastric cancer. , 2011, International journal of oncology.
[21] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[22] Michael A. Choti,et al. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.
[23] Andrew E. Teschendorff,et al. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. , 2010, Methods.
[24] S. Beck,et al. AutoMeDIP-seq: A high-throughput, whole genome, DNA methylation assay , 2010, Methods.
[25] S. T. Mees,et al. SERPINB5 and AKAP12 -- Expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma , 2010, BMC Cancer.
[26] 井伊 正則. Coexpression of laminin beta 3 and gamma 2 chains and epigenetic inactivation of laminin alpha 3 chain in gastric cancer , 2010 .
[27] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[28] Ahmed Essaghir,et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas , 2009, Modern Pathology.
[29] Derek Y. Chiang,et al. High‐resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss , 2008, Genes, chromosomes & cancer.
[30] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Scarpa,et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.
[32] S. Ogino,et al. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high , 2007, BMC Cancer.
[33] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[34] A. Gazdar,et al. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] B Nebiyou Bekele,et al. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.